Could a bionic pancreas simplify diabetes care in your Doctor's office?

NCT ID NCT07011147

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares the iLet Bionic Pancreas, an automated insulin delivery system, to standard care for adults with type 1 or type 2 diabetes who use insulin. About 240 participants will use the device for 13 weeks or continue their usual routine. The goal is to see if the device improves blood sugar control and is safe when prescribed by primary care providers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iLet Bionic Pancreas device
What this could lead to
If successful, this could make advanced insulin delivery technology more accessible through primary care, improving blood sugar control for many people with diabetes.
What could go wrong
This is a relatively small, 13-week study in primary care, so results may not apply to all patients or settings. The device may not work as well for everyone, and there are risks of low blood sugar or device issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • University of Colorado Anschutz Medical Campus

    RECRUITING

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.